Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

AKAP18δ Anchors and Regulates CaMKII Activity at Phospholamban-SERCA2 and RYR.

Autor: Carlson CR; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.)., Aronsen JM; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.).; Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo Norway (J.M.A.).; Department of Pharmacology, Oslo University Hospital, Norway (J.M.A.)., Bergan-Dahl A; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.).; The KG Jebsen Cardiac Research Center, University of Oslo, Norway (A.B.-D., M.L., P.K.L., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.)., Moutty MC; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.C.M., E.K.)., Lunde M; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.).; The KG Jebsen Cardiac Research Center, University of Oslo, Norway (A.B.-D., M.L., P.K.L., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.)., Lunde PK; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.).; The KG Jebsen Cardiac Research Center, University of Oslo, Norway (A.B.-D., M.L., P.K.L., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.)., Jarstadmarken H; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.)., Wanichawan P; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.)., Pereira L; Department of Pharmacology, University of California at Davis (L.P., D.M.B.)., Kolstad TRS; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.).; The KG Jebsen Cardiac Research Center, University of Oslo, Norway (A.B.-D., M.L., P.K.L., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.)., Dalhus B; Department of Microbiology, Oslo University Hospital, Norway (B.D.).; Department of Medical Biochemistry, Institute for Clinical Medicine, University of Oslo, Norway (B.D.)., Subramanian H; Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (H.S., V.N.).; German Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Germany (H.S., S.H., O.J.M., V.N.)., Hille S; German Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Germany (H.S., S.H., O.J.M., V.N.).; Department of Internal Medicine III, University of Kiel, Kiel, Germany (S.H., O.J.M.)., Christensen G; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.).; The KG Jebsen Cardiac Research Center, University of Oslo, Norway (A.B.-D., M.L., P.K.L., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.)., Müller OJ; German Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Germany (H.S., S.H., O.J.M., V.N.).; Department of Internal Medicine III, University of Kiel, Kiel, Germany (S.H., O.J.M.)., Nikolaev V; Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (H.S., V.N.).; German Centre for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Germany (H.S., S.H., O.J.M., V.N.)., Bers DM; Department of Pharmacology, University of California at Davis (L.P., D.M.B.)., Sjaastad I; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.).; The KG Jebsen Cardiac Research Center, University of Oslo, Norway (A.B.-D., M.L., P.K.L., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.)., Shen X; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.).; The KG Jebsen Cardiac Research Center, University of Oslo, Norway (A.B.-D., M.L., P.K.L., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.)., Louch WE; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.).; The KG Jebsen Cardiac Research Center, University of Oslo, Norway (A.B.-D., M.L., P.K.L., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.)., Klussmann E; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.C.M., E.K.).; German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Germany (E.K.)., Sejersted OM; Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (C.R.C., J.M.A., A.B.-D., M.L., P.K.L., H.J., P.W., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.).; The KG Jebsen Cardiac Research Center, University of Oslo, Norway (A.B.-D., M.L., P.K.L., T.R.S.K., G.C., I.S., X.S., W.E.L., O.M.S.).

Publikováno v: Circulation research [Circ Res] 2022 Jan 07; Vol. 130 (1), pp. 27-44. Date of Electronic Publication: 2021 Nov 24.

Highly functionalized terpyridines as competitive inhibitors of AKAP-PKA interactions.

Autor: Schäfer G; Max Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Strasse 10, 13125 Berlin (Germany)., Milić J, Eldahshan A, Götz F, Zühlke K, Schillinger C, Kreuchwig A, Elkins JM, Abdul Azeez KR, Oder A, Moutty MC, Masada N, Beerbaum M, Schlegel B, Niquet S, Schmieder P, Krause G, von Kries JP, Cooper DM, Knapp S, Rademann J, Rosenthal W, Klussmann E

Publikováno v: Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2013 Nov 11; Vol. 52 (46), pp. 12187-91. Date of Electronic Publication: 2013 Sep 23.

Importin α/β mediates nuclear import of individual SUMO E1 subunits and of the holo-enzyme.

Autor: Moutty MC; Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Alliance, Heidelberg, Germany. f.melchior@zmbh.uni-heidelberg.de, Sakin V, Melchior F

Publikováno v: Molecular biology of the cell [Mol Biol Cell] 2011 Mar 01; Vol. 22 (5), pp. 652-60. Date of Electronic Publication: 2011 Jan 05.

A novel calmodulin-Ca2+ target recognition activates the Bcl-2 regulator FKBP38.

Autor: Edlich F; Max Planck Research Unit for Enzymology of Protein Folding, Weinbergweg 22, D-06120 Halle/Saale, Germany. edlich@enzyme-halle.mpg.de, Maestre-Martínez M, Jarczowski F, Weiwad M, Moutty MC, Malesević M, Jahreis G, Fischer G, Lücke C

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2007 Dec 14; Vol. 282 (50), pp. 36496-504. Date of Electronic Publication: 2007 Oct 17.